Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter Sells 1,000 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now directly owns 26,259 shares of the company’s stock, valued at $11,500,916.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Garnreiter also recently made the following trade(s):

• On Monday, September 16th, Michael Garnreiter sold 1,000 shares of Axon Enterprise stock. The stock was sold at an average price of $380.99, for a total value of $380,990.00.

Axon Enterprise Stock Down 0.1 %

NASDAQ:AXON traded down $0.29 during trading hours on Wednesday, reaching $433.83. 375,993 shares of the stock were exchanged, compared to its average volume of 523,883. Axon Enterprise, Inc. has a twelve month low of $199.29 and a twelve month high of $440.89. The firm has a 50 day moving average of $384.24 and a 200 day moving average of $329.30. The stock has a market cap of $32.78 billion, a PE ratio of 114.54, a PEG ratio of 11.49 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same period in the previous year, the company earned $0.80 earnings per share. The company’s quarterly revenue was up 34.5% on a year-over-year basis. On average, equities analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AXON. Jefferies Financial Group began coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective on the stock. Northland Securities lifted their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Craig Hallum lifted their price target on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Bank of America began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target for the company. Finally, Robert W. Baird upped their target price on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. SPC Financial Inc. boosted its stake in Axon Enterprise by 2.2% during the 3rd quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 38 shares during the last quarter. Wolff Wiese Magana LLC bought a new position in Axon Enterprise in the 3rd quarter worth approximately $237,000. Vontobel Holding Ltd. lifted its holdings in shares of Axon Enterprise by 58.6% in the third quarter. Vontobel Holding Ltd. now owns 4,066 shares of the biotechnology company’s stock worth $1,625,000 after buying an additional 1,503 shares in the last quarter. Magnus Financial Group LLC grew its position in Axon Enterprise by 3.2% during the third quarter. Magnus Financial Group LLC now owns 2,280 shares of the biotechnology company’s stock worth $911,000 after buying an additional 70 shares in the last quarter. Finally, Swedbank AB lifted its holdings in shares of Axon Enterprise by 1.7% during the 3rd quarter. Swedbank AB now owns 132,603 shares of the biotechnology company’s stock worth $52,988,000 after acquiring an additional 2,206 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.